{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:00:56Z","timestamp":1791975656689,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.ejphar.2004.07.097","type":"journal-article","created":{"date-parts":[[2004,9,8]],"date-time":"2004-09-08T14:32:55Z","timestamp":1094653975000},"page":"107-116","source":"Crossref","is-referenced-by-count":48,"title":["Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist"],"prefix":"10.1016","volume":"499","author":[{"given":"Claire L.","family":"Neilan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Husbands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Breeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C. (Holden)","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario D.","family":"Aceto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2004.07.097_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(97)81924-3","article-title":"Etorphines: \u03bc-opioid receptor-selective antinociception and low physical dependence capacity","volume":"338","author":"Aceto","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"479","key":"10.1016\/j.ejphar.2004.07.097_bib2","first-page":"9","article-title":"Long-term agonist effects of congeners of etorphine suggest interfacial location of mu opioid recognition site","volume":"23","author":"Bell","year":"1997","journal-title":"Abstr.-Soc. Neurosci."},{"key":"10.1016\/j.ejphar.2004.07.097_bib3","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1021\/ja00989a032","article-title":"Novel analgesics and molecular rearrangements in the morphine\u2013thebaine group: III. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylmorphine and -narcodeine","volume":"89","author":"Bentley","year":"1967","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejphar.2004.07.097_bib4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1037\/1064-1297.3.4.477","article-title":"Buprenorphine treatment of opioid dependence: a review","volume":"3","author":"Bickel","year":"1995","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2004.07.097_bib5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0006-8993(89)91432-7","article-title":"Chronic morphine increases \u03bc-opiate receptor binding in rat brain: a quantitative autoradiographic study","volume":"477","author":"Brady","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2004.07.097_bib6","first-page":"257","article-title":"A new consistent model explaining structure (conformation)-activity relationships of opiates with \u03bc-selectivity","volume":"10","author":"Brandt","year":"1993","journal-title":"Drug Des. Discov."},{"key":"10.1016\/j.ejphar.2004.07.097_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF02245071","article-title":"Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on \u03ba-opioid agonists in the mouse writhing assay","volume":"115","author":"Broadbear","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2004.07.097_bib8","first-page":"933","article-title":"Methocinnamox is a potent, long-lasting and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, \u03b2-funaltrexamine and \u03b2-chlornaltrexamine","volume":"294","author":"Broadbear","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib9","first-page":"1195","article-title":"BU48: a novel buprenorphine analog that exhibits \u03b4-opioid-mediated convulsions but not delta-mediated antinociception in mice","volume":"294","author":"Broom","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/jpet.102.036525","article-title":"Comparison of receptor mechanisms and efficacy requirements for \u03b4-agonist induced convulsive activity and antinociception in mice","volume":"303","author":"Broom","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1476-5381.1977.tb07533.x","article-title":"The animal pharmacology of buprenorphine: an oripavine analgesic agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2004.07.097_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","article-title":"Agonist and antagonist properties of buprenorphine, a new antinociceptive agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2004.07.097_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0160-5402(86)90056-2","article-title":"A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys","volume":"15","author":"Dykstra","year":"1986","journal-title":"J. Pharmacol. Methods"},{"key":"10.1016\/j.ejphar.2004.07.097_bib14","first-page":"385","article-title":"Synthetic analgesics: II. Dithienylbutenyl- and dithienylbutylamines","volume":"107","author":"Eddy","year":"1953","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib15","first-page":"652","article-title":"Discriminative stimulus effects of reversible and irreversible opiate antagonists: morphine, oxymorphazone and buprenorphine","volume":"230","author":"France","year":"1984","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib16","series-title":"Buprenorphine: Combatting Drug Abuse with a Unique Opioid","first-page":"213","article-title":"Clinical efficacy studies of buprenorphine for the treatment of opiate dependence","author":"Fudala","year":"1995"},{"key":"10.1016\/j.ejphar.2004.07.097_bib17","series-title":"Opiates and Endogenous Opioid Peptides","first-page":"295","article-title":"The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics","author":"Hambrook","year":"1976"},{"key":"10.1016\/j.ejphar.2004.07.097_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(00)00176-X","article-title":"Antinociceptive and other behavioral effects of the steroid SC17599 are mediated by the \u03bc-opioid receptor","volume":"395","author":"Houshyar","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2004.07.097_bib19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1476-5381.1975.tb07373.x","article-title":"Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics","volume":"53","author":"Hughes","year":"1975","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2004.07.097_bib20","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/0960-894X(95)00522-1","article-title":"Morphinan cyclic imines and pyrrolidines containing a constrained phenyl group: high affinity opioid agonists","volume":"5","author":"Husbands","year":"1995","journal-title":"Bioorganic Med. Chem. Letters"},{"key":"10.1016\/j.ejphar.2004.07.097_bib21","article-title":"A bridged pyrrolomorphinan with potent, long-lasting \u03ba-opioid agonism and delayed opioid antagonism","author":"Husbands","year":"2003","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.ejphar.2004.07.097_bib22","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/0024-3205(93)90728-L","article-title":"The pharmacology of salmeterol","volume":"52","author":"Johnson","year":"1993","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2004.07.097_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3940(96)12942-6","article-title":"Agonist and antagonist properties of dihydroetorphine for mu-opioid receptors in mice","volume":"215","author":"Kamei","year":"1996","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2004.07.097_bib24","first-page":"412","article-title":"Acetic acid for analgesic screening","volume":"18","author":"Koster","year":"1959","journal-title":"Fed. Proc."},{"key":"10.1016\/j.ejphar.2004.07.097_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0014-2999(99)00460-4","article-title":"Differential binding properties of oripavines at cloned mu- and delta-opioid receptors","volume":"378","author":"Lee","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2004.07.097_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"139","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2004.07.097_bib27","first-page":"304","article-title":"Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of \u03bc-selective agonist and antagonist activity","volume":"289","author":"McLaughlin","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1476-5381.1969.tb07964.x","article-title":"The inhibitory action of noradrenaline and adrenaline in acetylcholine output on guinea-pig longitudinal muscle strip","volume":"35","author":"Paton","year":"1969","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2004.07.097_bib29","first-page":"319","article-title":"Inhibition of writhing by narcotic antagonists","volume":"154","author":"Pearl","year":"1966","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3727\/107156995819563122","article-title":"Molecular modeling of fumaramido and cinnamoylamido derivatives in epoxy-morphinans. Correlation with pharmacological profiles","volume":"1","author":"Piggot","year":"1995","journal-title":"Analgesia"},{"key":"10.1016\/j.ejphar.2004.07.097_bib31","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1021\/jm00364a001","article-title":"Different receptor sites mediate opioid agonism and antagonism","volume":"26","author":"Portoghese","year":"1983","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2004.07.097_bib32","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1021\/jm00073a015","article-title":"14\u03b2-p-Nitrocinnamoylamino-7,8-dihydromorphinones and their codeinone analogues: synthesis and receptor activity","volume":"36","author":"Sebastian","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2004.07.097_bib33","series-title":"Manual of Pharmacological Calculations with Computer Programs","author":"Tallarida","year":"1987"},{"key":"10.1016\/j.ejphar.2004.07.097_bib34","first-page":"809","article-title":"Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment","volume":"240","author":"Tao","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-3806(88)90176-9","article-title":"Morphine-induced down regulation of \u03bc-opioid receptors in neonatal rat brain","volume":"41","author":"Tempel","year":"1988","journal-title":"Dev. Brain Res."},{"key":"10.1016\/j.ejphar.2004.07.097_bib36","first-page":"848","article-title":"Modulation by opioid agonists of guanine-5\u2032-O-(3-[35]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells","volume":"47","author":"Traynor","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2004.07.097_bib37","first-page":"1093","article-title":"Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C20 hydroxyl group","volume":"291","author":"Traynor","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1476-5381.1980.tb07041.x","article-title":"A classification of opiate receptors that mediate antinociception in animals","volume":"69","author":"Tyers","year":"1980","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2004.07.097_bib39","first-page":"195","article-title":"Methoclocinnamox: a \u03bc partial agonist with pharmacotherapeutic potential for heroin abuse","volume":"147","author":"Woods","year":"1995","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.ejphar.2004.07.097_bib40","first-page":"314","article-title":"Opioid receptor regulation in mice","volume":"265","author":"Yoburn","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2004.07.097_bib41","first-page":"676","article-title":"Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTP\u03b3S binding to membranes: determination of potencies and efficacies of ligands","volume":"282","author":"Zhu","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299904008313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299904008313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T14:55:29Z","timestamp":1624632929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299904008313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":41,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0014299904008313"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2004.07.097","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}